BioRestorative Therapies (BRTX) Total Liabilities (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Total Liabilities came in at $4.1 million in Q4 2025, up 8.84% YoY from $3.7 million in Q4 2024, and down 27.7% on a QoQ basis from $5.6 million in Q3 2025.
BioRestorative Therapies (BRTX) Total Liabilities (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Total Liabilities data on file, last reported at $4.1 million in Q4 2025.
- Quarterly Total Liabilities rose 8.84% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (up 8.84% YoY) and the FY2025 annual result came in at $4.1 million, up 8.84% from the prior year.
- Total Liabilities slipped to $4.1 million in Q4 2025, from $5.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $15.0 million in Q1 2022 to a low of $856497.0 in Q4 2021.
- A 5-year average of $5.8 million and a median of $5.5 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities slumped 84.92% — and 2022, when it surged 617.38%.
- Tracing BRTX's Total Liabilities over 5 years: stood at $856497.0 in 2021, then surged by 617.38% to $6.1 million in 2022, then plunged by 57.57% to $2.6 million in 2023, then surged by 43.76% to $3.7 million in 2024, then increased by 8.84% to $4.1 million in 2025.
- The last three Total Liabilities figures came in at $4.1 million (Q4 2025), $5.6 million (Q3 2025), and $3.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 5.64 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Sep 30, 2024 | 4.58 Mn |
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | 3.04 Mn |
| Jun 30, 2023 | 10.66 Mn |
| Mar 31, 2023 | 7.62 Mn |
| Dec 31, 2022 | 6.14 Mn |
| Sep 30, 2022 | 8.14 Mn |
| Jun 30, 2022 | 7.29 Mn |
| Mar 31, 2022 | 14.97 Mn |
| Dec 31, 2021 | 856,497.00 |
| Sep 30, 2021 | 7.05 Mn |
| Jun 30, 2021 | 6.69 Mn |
| Mar 31, 2021 | 6.40 Mn |